What kind of drug does benzalantamine belong to, and is it on the market now?

Benzgalantamine (benzgalantamine), trade name Zunveyl, is an emerging cholinesterase inhibitor specifically developed for the treatment of mild to moderate dementia of the Alzheimer's type in adults. Alzheimer's disease, a degenerative brain disease that gradually erodes patients' memory and thinking abilities, is the most common type of dementia among the elderly. Although scientists have intensively studied the exact cause of cognitive impairment, its mysteries have not yet been fully revealed. However, the degeneration of acetylcholine-producing neurons in the brain is widely considered to be one of the important factors driving the development of the disease.

Bengalantamine, as a prodrug of galantamine, holds great promise for the treatment of Alzheimer's disease. Galantamine, a well-established drug that has been used to treat Alzheimer's disease, has won widespread recognition in the medical community for its remarkable efficacy since it first received regulatory approval in 2001 under the trade name Reminyl. Subsequently, in 2005, its trade name was changed to Razadyne, which continues to bring treatment hope to many patients. As a competitive and reversible acetylcholinesterase inhibitor, galantamine effectively increases the concentration of acetylcholine in the brain by reversibly inhibiting the hydrolysis of acetylcholine by cholinesterase, thereby improving the patient's cognitive and memory functions.

Bengalantamine is a sustained-release oral tablet further optimized on the basis of galantamine. Its unique design includes an enteric coating, which significantly reduces the incidence of gastrointestinal adverse reactions. Bengalantamine remains inert as the drug passes through the stomach and does not release the active ingredient until it reaches the intestines. This property not only improves the bioavailability of the drug, but also significantly enhances patient tolerance, allowing patients to better adhere to treatment.

On July 26, 2024, benzalantamine Zunveyl was approved by the U.S. Food and Drug Administration (FDA). This milestone progress undoubtedly brings new treatment hope to patients with Alzheimer's disease. However, it is worth noting that as of February 2025, this innovative drug has not yet been approved for marketing in my country. Therefore, domestic patients are temporarily unable to directly purchase the treatment convenience and potential benefits brought by this new drug.

As the global aging problem becomes increasingly severe, the demand for treatment of Alzheimer's disease continues to rise. BengalantamineAs a new and highly effective cholinesterase inhibitor, Zunveyl’s future launch will undoubtedly bring good news to more patients. The drug is expected to significantly improve patients' quality of life, reduce their symptoms of cognitive impairment, and slow the progression of the disease. We sincerely hope that benzalantamine will be approved for marketing in China as soon as possible to provide more treatment options for patients with Alzheimer's disease. This will allow patients to be more calm when facing this stubborn disease, while also providing doctors and researchers with more treatment methods and research directions.

Reference link:https://www.drugs.com/pro/zunveyl.html#S12.3